Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention or after acute coronary syndrome : Practical lessons from a review.

An unexpected, but important finding was a borderline significant ( p = 0.05) excess mortality (all-cause death 2.0% in prolonged DAPT vs. 1.5% in placebo-treated patients) due to more non-cardiovascular deaths [ 25 , 26 ].

also in 9,411 other papers